Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes. This story matters for Finance & Markets readers tracking finance. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. InvestorsWire curates and briefs the finance & markets stories that matter. Our editorial policy →